The 81st JSAP Autumn Meeting, 2020

Presentation information

Oral presentation

12 Organic Molecules and Bioelectronics » 12.7 Biomedical Engineering and Biochips

[9a-Z12-1~11] 12.7 Biomedical Engineering and Biochips

Wed. Sep 9, 2020 9:00 AM - 12:00 PM Z12

Toshihiko Noda(Toyohashi Univ. of Tech.), Tetsu Tanaka(Tohoku Univ.)

9:15 AM - 9:30 AM

[9a-Z12-2] Detection of α-Synuclein in serum of patients with Parkinson’s disease by liposome-immobilized cantilever sensor

〇(M2)Ryoko Kobayashi1, Masanori Sawamura2, Hodaka Yamakado2, Masayuki Sohgawa3, Minoru Noda1 (1.Kyoto Inst. Tech., 2.Kyoto Univ., 3.Niigata Univ.)

Keywords:biosensor, alpha-synclein, liposome

α-synuclein (αSyn) has been majorly recognized as causative agent for Parkinson Disease (PD). Its monomer usually existing in our brain cell starts to aggregate and grow as oligomers, protofibrils and fibrils, which are recognized to be toxic. Therefore, the detection of a trace amount of the αSyn fibril is essential for early diagnosis of PD.
We have previously applied the methods of protein misfolding cyclic amplification (PMCA) and real-time quaking-induced conversion (RT-QuIC) for label-free liposome-immobilized cantilever sensor in order to obtain a trace amount of chronological behavior of mouse-derived recombinant αSyn, realizing its fibrillar detection as small as 700 fM, which showed nearly the same detectivity as recent ELISA’s. Thereafter, we proceeded to detect the fibrillization of human-derived recombinant αSyn with the same ultralow concentration, although the fibrillization of human-derived is recognized less active than that of mouse-derived. This time, we targeted αSyn in the serum of PD patients and were able to confirm the same level of detection ability as the recombinant αSyn.